# Guardian Bio

Source: https://onco.cc/companies/guardian-bio/  
OnCo record `guardian-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Guardian Bio turns a patient's stem cells into dendritic cells, the immune system's teachers, trains them against that patient's tumour and gives them back to restart the immune attack.

## Summary

Guardian Bio is developing a dendritic cell therapy platform: patient-derived stem cells are differentiated into therapeutic dendritic cells, loaded against multiple antigens from the patient's own tumour and reinfused to activate cytotoxic T cells and natural killer cells. The rationale is that dendritic cell dysfunction in cancer patients limits the effect of other immunotherapies. The company is preclinical with a very small team; no sourced financing rounds are recorded.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: Boston, MA
- Type: cell-therapy
- Website: https://www.guardian-bio.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/guardian-bio
- Official website: https://www.guardian-bio.com

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/guardian-bio.json